Eisai is a global research and development-based pharmaceutical company striving for SEIZURE FREEDOM to people living with epilepsy. It is supported throughout the company by our guiding philosophy of human health care (hhc) which is to “give first thought to patients and their families and to increasing the benefits health care provides”.

UCB, Brussels, Belgium is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or the central nervous system. With more than 8300 people in approximately 36 countries, UCB generated revenue of € 5.3 billion in 2020.

BioMarin has been pioneering rare disease for more than two decades, with multiple commercialized products and a growing pipeline of product candidates for serious and life-threatening rare genetic diseases.

At BioMarin, we view ourselves as a team of pioneers—willing to take risks in the quest to find new solutions to address the biggest challenges in rare disease and motivated by the desire to help improve the lives of patients with unmet medical needs.

GW Pharmaceuticals is a UK-based biopharmaceutical company that has established a world-leading position in cannabinoid science and medicine and was listed as one of TIME magazine’s ‘50 Genius Companies Inventing the Future, 2018’. Our mission is to unlock the potential of the cannabis plant through rigorous scientific investigations and extensive clinical trials, to improve the lives of seriously ill patients. Our pioneering work has led to the regulatory approval of world-first, potentially life-improving, cannabis-based medicines.1–3

Patients are our key focus, and improving their quality of life is our motivation.

Job code: VV-MED-17398

Date of preparation: January 2021